Brenda Yunqing Wu MD PhD

Neurology•New Brunswick, NJ

Epilepsy, Neurophysiology

Board certified neurologist subspecialized in Clinical Neurophysiology/epilepsy

Join to View Full Profile

219 Livingston Ave., Unit ANew Brunswick, NJ 08901
Phone+1 732-258-0061
Fax+1 732-993-9497

Education & Training

Yale-New Haven Medical CenterFellowship, Epilepsy, 2002 - 2003
University of FloridaFellowship, Clinical Neurophysiology, 2001 - 2002
Albany Medical CenterResidency, Neurology, 1998 - 2001
Albany Medical CenterInternship, Internal Medicine, 1997 - 1998
Albany Medical CollegePhD, pharmacology & neuroscience, Excellence in Research, 1992 - 1996
Sun Yat-Sen University of Medical ScienceClass of 1990

Certifications & Licensure

NJ State Medical License 2003 - 2025
FL State Medical License 2001 - 2005
CT State Medical License 2002 - 2003
American Board of Psychiatry and Neurology Neurology
American Board of Clinical NeurophysiologyCNS-Epilepsy

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures. Start of enrollment: 2006 Jan 01
Completed
Phase 3
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures Start of enrollment: 2006 Jun 01
Completed
Phase 2
Conversion to Monotherapy Study With Keppra XR for Partial Seizures Start of enrollment: 2007 Aug 01
Completed
Phase 3
Clobazam in Patients With Lennox-Gastaut Syndrome Start of enrollment: 2007 Aug 01
Completed
Phase 3
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy. Start of enrollment: 2007 Nov 01
Terminated
Phase 3
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. Start of enrollment: 2009 Jan 01
Completed
Phase 3
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures Start of enrollment: 2009 Jan 01
Completed
Phase 3
Eslicarbazepine Acetate Monotherapy Long Term Study Start of enrollment: 2009 Aug 01
Completed
Phase 3
Phase 3 Randomized, Dlouble-Blind, Parallel, Placebo-Controlled, Multicenter Study, With Optional Open-Label Continuation, of the Efficacy and Safety of Vanquix Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory, Patients With E Start of enrollment: 2008 Mar 01
Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome Start of enrollment: 2005 Dec 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Survey of risk factors for osteoporosis and osteoprotective behaviors among patients with epilepsy
Marianna Fedorenko, Mary L. Wagner, Brenda Y. Wu
Epilepsy & Behavior. 2015-04-01

Professional Memberships

American Academy of Neurology - AAN
Member
American Epilepsy Society - AES
Member
American Clinical Neurophysiology Society
Member

Other Languages

Chinese (Cantonese), Chinese (Mandarin)

External Links

Tebrahttps://provider.kareo.com/brenda-wu